SPRY · ARS Pharmaceuticals, Inc.
$5.93
-0.07 (-1.17%)
At close · Jul 24
Market Cap
$589.86M
Shares
99.30M
ARS Pharmaceuticals, Inc. Earnings Call Transcripts
Every quarterly earnings call for ARS Pharmaceuticals, Inc. (SPRY) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
▲4900%
$500,000
−$12.52M
'24 Q2
24-08-09
·
$2.07M
−$19.13M
'24 Q3
24-11-13
·
$86.58M
$49.93M
'24 Q4
25-03-20
·
$7.97M
−$33.94M
'25 Q1
25-05-14
▲3043.4%
$15.72M
−$44.88M
'25 Q2
25-08-13
▲1471.6%
$32.50M
−$51.15M
'25 Q3
25-11-10
▼67.6%
$28.09M
−$41.32M
'25 Q4
26-03-09
LATEST
▲184.5%
$22.68M
−$60.62M
'26 Q1
26-05-15
Earnings call
FY26 · Q1
2026-05-15
ARS Pharmaceuticals, Inc. Q1 FY2026 Earnings Call
Revenue
$22.68M
▲ 184.5% YoY Diluted EPS
$-0.61
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-03-09
ARS Pharmaceuticals, Inc. Q4 FY2025 Earnings Call
Positive tone
Neffy clinical profile and real-world data
Direct-to-consumer campaign and patient engagement
Payer access and prior authorization
Revenue
$28.09M*
▼ 67.6% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-10
ARS Pharmaceuticals, Inc. Q3 FY2025 Earnings Call
Confident tone
U.S. neffy revenue growth
International expansion
Get neffy On Us virtual prescribing program
Revenue
$32.50M
▲ 1471.6% YoY Diluted EPS
$-0.52
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-13
ARS Pharmaceuticals, Inc. Q2 FY2025 Earnings Call
Confident tone
neffy U.S. commercial momentum and revenue growth
Payer access and prior authorization progress
DTC advertising campaign
Revenue
$15.72M
▲ 3043.4% YoY Diluted EPS
$-0.46
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-14
ARS Pharmaceuticals, Inc. Q1 FY2025 Earnings Call
Confident tone
neffy Commercial Launch and Revenue Growth
neffy Experience Program and Physician Adoption
Pediatric Dose (1 mg) Approval
Revenue
$7.97M
Diluted EPS
$-0.35
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-03-20
ARS Pharmaceuticals, Inc. Q4 FY2024 Earnings Call
Confident tone
neffy launch trajectory
Payer coverage and prior authorization
Pediatric label expansion
Revenue
$86.58M*
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-13
ARS Pharmaceuticals, Inc. Q3 FY2024 Earnings Call
Confident tone
neffy U.S. launch progress
Physician adoption and education
International partnerships and licensing
Revenue
$2.07M
Diluted EPS
$-0.20
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-09
ARS Pharmaceuticals, Inc. Q2 FY2024 Earnings Call
Revenue
$500,000
▲ 4900% YoY Diluted EPS
$-0.13
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-03-31
ARS Pharmaceuticals, Inc. Q4 FY2021 Earnings Call
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Showing 1–9 of 9 earnings calls